Ebola Virus VP40 C-terminal Lysine Residue Mediates Lipid Interactions and Dimer-Dimer Interactions
Journal of Biological Chemistry · 2026-10 · 113709
DOI: 10.1016/j.jbc.2026.113709 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026-10. Verfasst von Hannah M Woods und 6 weiteren Autor:innen. Beteiligte Einrichtung: Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, National Institutes of Health Office of the Director.
Abstract (Originalsprache)
The Ebola virus (EBOV) matrix protein VP40 is the main driver of viral assembly and budding, processes which depend on its ability to oligomerize at the inner leaflet of the plasma membrane (PM). VP40 forms dimers in the cytoplasm that traffic to the membrane and assemble into higher-order oligomers, but the specific molecular determinants governing the stability of these oligomeric interfaces are not fully understood. Here, we investigate the role of the C-terminal lysine residue, Lys326, in mediating VP40-lipid and VP40-VP40 interactions. Using a combination of molecular dynamics simulations and computational site-saturation mutagenesis, we predicted that while Lys326 has a minimal role in the stability of the isolated VP40 dimer, it is a critical determinant in stabilizing the interfaces of higher-order structures like tetramers and hexamers. Experimentally, mutation of this residue to alanine or aspartic acid (K326A or K326D) impaired VP40 PM localization, oligomerization, and in a charge-dependent manner, virus-like particle production. Our results indicate that a cationic residue is crucial not only for interactions with anionic phospholipids in the PM but, more importantly, for forming stabilizing networks across VP40 dimer-dimer interfaces. Together, these findings identify Lys326 as a keystone residue that couples membrane binding to the stabilization of essential higher-order oligomers, revealing a critical interface for EBOV assembly that could be exploited for future antiviral strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA.
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
- Department of Physics, Florida International University, Miami, FL 33199, USA.
- Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada.
- Department of Physics, Florida International University, Miami, FL 33199, USA; Biomolecular Sciences Institute, Florida International University, Miami, FL 33199, USA.
- Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA. Electronic address: rstaheli@purdue.edu.
Förderung
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health Office of the Director
Zitieren
APA
Woods, H. M., Narkhede, Y. B., Karki, U., Norris, M. J., Chapagain, P. P., Wiest, O., & Stahelin, R. V. (2026). Ebola Virus VP40 C-terminal Lysine Residue Mediates Lipid Interactions and Dimer-Dimer Interactions. Journal of Biological Chemistry, 113709. https://doi.org/10.1016/j.jbc.2026.113709
Vancouver
Woods HM, Narkhede YB, Karki U, Norris MJ, Chapagain PP, Wiest O, et al. Ebola Virus VP40 C-terminal Lysine Residue Mediates Lipid Interactions and Dimer-Dimer Interactions. Journal of Biological Chemistry. 2026:113709. doi:10.1016/j.jbc.2026.113709
BibTeX
@article{Woods2026,
author = {Woods, Hannah M and Narkhede, Yogesh B and Karki, Ukesh and Norris, Michael J and Chapagain, Prem P and Wiest, Olaf and Stahelin, Robert V},
title = {Ebola Virus VP40 C-terminal Lysine Residue Mediates Lipid Interactions and Dimer-Dimer Interactions},
journal = {Journal of Biological Chemistry},
year = {2026},
pages = {113709},
doi = {10.1016/j.jbc.2026.113709}
}
EUVIMED